TY - JOUR AU - Martinez, Nina L. AU - Glass, Jon AU - Shi, Wenyin PY - 2019 TI - Bevacizumab in recurrent glioblastoma JF - Translational Cancer Research; Vol 8, Supplement 2 (March 28, 2019): Translational Cancer Research Y2 - 2019 KW - N2 - In May 2009, the U.S. Food and Drug Administration granted accelerated approval for the use of bevacizumab in patients with progressive glioblastoma (GBM), the most common malignant primary brain tumor in adults (1). Neovascularization is a morphologic hallmark of GBM, driven in part by vascular endothelial growth factor A (VEGF-A) which is targeted and neutralized by bevacizumab. UR - https://tcr.amegroups.org/article/view/26303